More Articles

EMA launches public catalogue of drug shortages Pharma News | Posted 15/11/2013

The European Medicines Agency (EMA) announced on 4 November 2013 the launch of its public catalogue on supply shortages of drugs.

Etanercept biosimilar has comparable pharmacokinetics to Enbrel Biosimilars/Research | Posted 15/11/2013

An etanercept biosimilar (CHS-0214) from fledgling biotech company Coherus Biosciences (Coherus) has shown comparable pharmacokinetics in a pivotal clinical study.

South Africa to allow parallel imports and compulsory licensing Policies & Legislation | Posted 15/11/2013

Just two months after releasing a draft policy on intellectual property, South Africa has announced that it will also amend its patent legislation to allow parallel imports and compulsory licensing.

American-made prescription drugs 76% cheaper when purchased abroad Reports | Posted 15/11/2013

American patients can make significant savings by buying drugs abroad, according to an analysis carried out by online pharmacy information specialist PharmacyChecker.com.

Similar biotherapeutic products under development in Latin America Biosimilars/General | Posted 15/11/2013

Last update: 15 November 2013Similar biotherapeutic products are high on the health policy agenda in Latin America, due to the fact that they are less costly and therefore have the potential t...

Ranbaxy sues Actavis over generic acne drug Generics/News | Posted 15/11/2013

Indian generics giant Ranbaxy Laboratories (Ranbaxy) is suing US generic drugmaker Actavis to try to stop the latter marketing a generic version of Ranbaxy’s acne drug Absorica (isotretinoin).

Pharmaceutical expenditure as a health-expenditure indicator Generics/Research | Posted 08/11/2013

Pharmaceutical expenditure is a major indicator in health-expenditure accounting, and is particularly useful to policymakers and researchers in making regional, country and international comparison...

Biosimilars: what patients need to know Reports | Posted 08/11/2013

Biosimilars are medicines that are similar to a biological medicine that has already been authorized. Biosimilars are different to generics in that they are not identical to their reference product...